These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 3039645)

  • 1. Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies.
    Dawson DM; Carter JL; Hafler DA; Weiner HL
    Riv Neurol; 1987; 57(2):88-91. PubMed ID: 3039645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
    Carter JL; Hafler DA; Dawson DM; Orav J; Weiner HL
    Neurology; 1988 Jul; 38(7 Suppl 2):9-14. PubMed ID: 2838768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
    Hauser SL; Dawson DM; Lehrich JR; Beal MF; Kevy SV; Propper RD; Mills JA; Weiner HL
    N Engl J Med; 1983 Jan; 308(4):173-80. PubMed ID: 6294517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis. II. A critical assessment of immunotherapy.
    Durelli L; Bergamini L
    Riv Neurol; 1989; 59(5):191-201. PubMed ID: 2483962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppression with monoclonal antibodies in multiple sclerosis.
    Hafler DA; Weiner HL
    Neurology; 1988 Jul; 38(7 Suppl 2):42-7. PubMed ID: 3260356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis.
    Bowen JD; Petersdorf SH; Richards TL; Maravilla KR; Dale DC; Price TH; St John TP; Yu AS
    Clin Pharmacol Ther; 1998 Sep; 64(3):339-46. PubMed ID: 9757158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of immunosuppressive agents and particularly of cyclophosphamide on lymphocytes subsets in treated multiple sclerosis patients.
    Gonsette RE; Defalque A; Demonty L
    Riv Neurol; 1987; 57(3):181-4. PubMed ID: 2960008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunosuppressive treatment im multiple sclerosis].
    Mertin J
    Fortschr Med; 1980 Oct; 98(37):1431-6. PubMed ID: 6253370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with cyclophosphamide in multiple sclerosis: the cons.
    Likosky WH
    Neurology; 1988 Jul; 38(7 Suppl 2):14-8. PubMed ID: 3290708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Non-specific immunosuppression and multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 1998 Sep; 154(8-9):629-34. PubMed ID: 9809379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating multiple sclerosis with monoclonal antibodies: the cons.
    Champlin RE
    Neurology; 1988 Jul; 38(7 Suppl 2):47-9. PubMed ID: 3260357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pulse-dose cyclophosphamide therapy for chronic progressive multiple sclerosis].
    Watanabe T; Yamamoto T; Saito T; Sugano M; Tsukamoto T
    Rinsho Shinkeigaku; 1993 Jan; 33(1):15-20. PubMed ID: 8334769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Open therapeutic trial of anti-T CD4 monoclonal antibody in multiple sclerosis].
    Rumbach L; Racadot E; Bataillard M; Galmiche J; Henlin JL; Trutmann M; Ziegler F; Wijdenes J
    Rev Neurol (Paris); 1994; 150(6-7):418-24. PubMed ID: 7747009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Steroid therapy in multiple sclerosis].
    Beer S; Kesselring J
    Schweiz Med Wochenschr; 1991 Jun; 121(26):961-9. PubMed ID: 1650496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo labeling of blood T cells: rapid traffic into cerebrospinal fluid in multiple sclerosis.
    Hafler DA; Weiner HL
    Ann Neurol; 1987 Jul; 22(1):89-93. PubMed ID: 3498435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The peculiar difficulties of therapeutic trials for multiple sclerosis.
    Myers LW; Ellison GW
    Neurol Clin; 1990 Feb; 8(1):119-41. PubMed ID: 1690838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute improvement in exacerbating multiple sclerosis produced by intravenous administration of mannitol.
    Stefoski D; Davis FA; Schauf CL
    Ann Neurol; 1985 Oct; 18(4):443-50. PubMed ID: 3000278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
    Gladstone DE; Zamkoff KW; Krupp L; Peyster R; Sibony P; Christodoulou C; Locher E; Coyle PK
    Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind study of true vs. sham plasmapheresis in patients being treated with immunosuppression for acute attacks of multiple sclerosis.
    Weiner HL; Dau PC; Khatri BO; Petajan J; Birnbaum G; McQuillen MP; Fosburg MT; Feldstein M; Orav J
    Prog Clin Biol Res; 1990; 337():283. PubMed ID: 2162062
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.